Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2847-2856

  Akazawa, Takashi ^a   Ohashi, Toshimitsu ^a,b   Nakajima, Hiroko ^c   Nishizawa, Yasuko ^a   Kodama, Ken ^d   Sugiura, Kikuya ^e   Inaba, Toshio ^e   Inoue, Norimitsu ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Yao Municipal Hospital   (Japan)

^e Osaka Prefecture University   (Japan)

Author keywords

Cancer immunotherapy; Immunoadjuvant; Lipopeptide; Toll like receptor

Indexed keywords

CD18 ANTIGEN; CYTOKINE; GLYCOPROTEIN P 15095; IMMUNOLOGICAL ADJUVANT; LIGAND; LIPOPEPTIDE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOLOGY; INFLAMMATION; KINETICS; LYMPH NODE; METABOLISM; MOUSE; NEOPLASM; PROCEDURES; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD18; ANTIGENS, NEOPLASM; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION; KINETICS; LIGANDS; LIPOPEPTIDES; LYMPH NODES; MICE; MICE, INBRED C57BL; NEOPLASMS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84908662243     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28939     Document Type: Article

References (46)

1. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002;1589:1-13.
2. Hemmi H, Takeuchi O, Kawai T, et al. A Tolllike receptor recognizes bacterial DNA. Nature 2000;408:740-5.
3. Tsuji S, Matsumoto M, Takeuchi O, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette- Guerin: involvement of toll-like receptors. Infect Immun 2000;68:6883-90.
4. Akazawa T, Masuda H, Saeki Y, et al. Adjuvantmediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88- deficient mice. Cancer Res 2004;64:757-64.
5. Nakajima H, Kawasaki K, Oka Y, et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004;53:617-24.
6. Kodama K, Higashiyama M, Takami K, et al. Innate immune therapy with a Bacillus Calmette- Guerin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study. Surg Today 2009;39:194-200.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
8. Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res 2007;67:7945-7.
9. Muraoka D, Kato T, Wang L, et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD81 T cells. J Immunol 2010;185:3768-76.
10. Muhlradt PF, Kiess M, Meyer H, et al. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997;185:1951-8.
11. Matsumoto M, Nishiguchi M, Kikkawa S, et al. Structural and functional properties of complement-activating protein M161Ag, a Mycoplasma fermentans gene product that induces cytokine production by human monocytes. J Biol Chem 1998;273:12407-14.
12. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-51.
13. Kang JY, Nan X, Jin MS, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009;31:873- 84.
14. Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007;130: 1071-82.
15. Hida T, Hayashi K, Yukishige K, et al. Synthesis and biological activities of TAN-1511 analogues. J Antibiot (Tokyo) 1995;48:589-603.
16. Reutter F, Jung G, Baier W, et al. Immunostimulants and Toll-like receptor ligands obtained by screening combinatorial lipopeptide collections. J Pept Res 2005;65:375-83.
17. Jackson DC, Lau YF, Le T, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004;101:15440-5.
18. Akazawa T, Inoue N, Shime H, et al. Adjuvant engineering for cancer immunotherapy: development of a synthetic TLR2 ligand with increased cell adhesion. Cancer Sci 2010;101:1596-603.
19. Okada N, Masunaga Y, Okada Y, et al. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther 2003;10: 421-31.
20. Harui A, Roth MD, Vira D, et al. Adenoviralencoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of alpha(v)beta3 integrins. J Leukoc Biol 2006;79: 1271-8.
21. Muhlradt PF, Kiess M, Meyer H, et al. Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect Immun 1998;66:4804-10.
22. Omueti KO, Beyer JM, Johnson CM, et al. Domain exchange between human toll-like receptors1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem 2005;280: 36616-25.
23. Sawahata R, Shime H, Yamazaki S, et al. Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2.Microbes Infect 2011;13:350-8.
24. Frick C, Odermatt A, Zen K, et al. Interaction of ICAM-1 with beta 2-integrin CD11c/CD18: characterization of a peptide ligand that mimics a putative binding site on domain D4 of ICAM-1.Eur J Immunol 2005;35:3610-21.
25. Helmich BK, Dutton RW. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 2001;166:6500-8.
26. Tanaka H, Mori Y, Ishii H, et al. Enhancement of metastatic capacity of fibroblast-tumor cell interaction in mice. Cancer Res 1988;48:1456-9.
27. Nakajima H, Oka Y, Tsuboi A, et al. Enhanced tumor immunity of WT1 peptide vaccination byinterferon-beta administration. Vaccine 2012;30: 722-9.
28. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000;164:1873-80.
29. Inaba K, Pack M, Inaba M, et al. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 1997;186:665-72.
30. Akazawa T, Shingai M, Sasai M, et al. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett 2007;581:3334-40.
31. Akazawa T, Ebihara T, Okuno M, et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 2007;104: 252-7.
32. Ohashi T, Akazawa T, Aoki M, et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer 2013;133: 1107-18.
33. Luhrmann A, Tschernig T, Pabst R, et al. Improved intranasal immunization with liveattenuated measles virus after co-inoculation of the lipopeptide MALP-2. Vaccine 2005;23:4721-6.
34. Nance SC, Yi AK, Re FC, et al. MyD88 is necessary for neutrophil recruitment in hypersensitivity pneumonitis. J Leukoc Biol 2008;83:1207-17.
35. Hailemichael Y, Dai Z, Jaffarzad N, et al. Persistent antigen at vaccination sites induces tumorspecific CD81 T cell sequestration, dysfunction and deletion. Nat Med 2013;19:465-72.
36. Erdman LK, Cosio G, Helmers AJ, et al. CD36and TLR interactions in inflammation and phagocytosis: implications for malaria. J Immunol 2009;183:6452-9.
37. Shamsul HM, Hasebe A, Iyori M, et al. The Tolllike receptor 2 (TLR2) ligand FSL-1 is internalized via the clathrin-dependent endocytic pathwaytriggered by CD14 and CD36 but not by TLR2. Immunology 2010;130:262-72.
38. Azuma M, Sawahata R, Akao Y, et al. The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One 2010;5:e12550.
39. Seya T, Matsumoto M, Tsuji S, et al. Structural- functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag. Microbes Infect 2002;4:955-61.
40. Buwitt-Beckmann U, Heine H, Wiesmuller KH, et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 2005; 35:282-9.
41. Degitz K, Li LJ, Caughman SW. Cloning and characterization of the 5'-transcriptional regulatory region of the human intercellular adhesion molecule 1 gene. J Biol Chem 1991;266:14024-30.
42. Ono M, Nomoto K, Nakazato S. Gene structure of rat testicular cell adhesion molecule 1 (TCAM- 1), and its physical linkage to genes coding for the growth hormone and BAF60b, a component of SWI/SNF complexes. Gene 1999;226:95-102.
43. Siu G, Hedrick SM, Brian AA. Isolation of the murine intercellular adhesion molecule 1 (ICAM- 1) gene. ICAM-1 enhances antigen-specific T cell activation. J Immunol 1989;143:3813-20.
44. Manning AM, Lu HF, Kukielka GL, et al. Cloning and comparative sequence analysis of the gene encoding canine intercellular adhesion molecule-1 (ICAM-1). Gene 1995;156:291-5.
45. Schmidt J, Welsch T, Jager D, et al. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 2007;97:598-604.
46. Mito K, Sugiura K, Ueda K, et al. IFN gamma markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models. Cancer Res 2010;70:7093-101.